Literature DB >> 3481323

Comparative pharmacokinetics of new quinolones.

H Lode1, G Höffken, C Prinzing, P Glatzel, R Wiley, P Olschewski, B Sievers, D Reimnitz, K Borner, P Koeppe.   

Abstract

The pharmacokinetic properties of the new quinolones are characterised by a high volume of distribution, long biological half-life, low serum protein binding, elimination mainly by the kidneys, high total and renal clearances, limited biotransformation and a moderate to excellent bioavailability after oral administration. However, each quinolone derivative (ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin) possesses individual pharmacokinetic characteristics, which should be considered in the treatment of patients, especially when liver and/or renal dysfunction exists.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481323     DOI: 10.2165/00003495-198700341-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  15 in total

1.  The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Absolute oral bioavailability of ciprofloxacin.

Authors:  G L Drusano; H C Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  Dose ranging study and constant infusion evaluation of ciprofloxacin.

Authors:  G L Drusano; K I Plaisance; A Forrest; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

4.  Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers.

Authors:  R D Cofsky; L duBouchet; S H Landesman
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].

Authors:  M Verho; E E Dagrosa; V Malerczyk
Journal:  Infection       Date:  1986       Impact factor: 3.553

6.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

7.  Pharmacokinetics of ciprofloxacin after oral and parenteral administration.

Authors:  G Höffken; H Lode; C Prinzing; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

8.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

9.  Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.

Authors:  A M Frydman; Y Le Roux; M A Lefebvre; F Djebbar; J B Fourtillan; J Gaillot
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

10.  Pharmacokinetics of ciprofloxacin after intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; I M Kolstad; S Johnsen
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

View more
  12 in total

1.  Microbiological transformation of enrofloxacin by the fungus Mucor ramannianus.

Authors:  I A Parshikov; J P Freeman; J O Lay; R D Beger; A J Williams; J B Sutherland
Journal:  Appl Environ Microbiol       Date:  2000-06       Impact factor: 4.792

2.  Milk and yoghurt do not impair the absorption of ofloxacin.

Authors:  P J Neuvonen; K T Kivistö
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.

Authors:  L Rabbaa; S Dautrey; N Colas-Linhart; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 5.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  Penetration of ofloxacin into human lung tissue following a single oral dose of 200 milligrams.

Authors:  F Serour; M Dan; A Gorea; A Yellin; Y Lieberman; S A Berger
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

8.  Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.

Authors:  J H Yuk; C H Nightingale; R Quintiliani; K R Sweeney
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

9.  Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.

Authors:  D Girard; T D Gootz; P R McGuirk
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 10.  Ofloxacin pharmacokinetics in chronic renal failure and dialysis.

Authors:  N Lameire; B Rosenkranz; V Malerczyk; K H Lehr; N Veys; S Ringoir
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.